Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market To be extracted
Other Market Stock Code To be extracted
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameBeone Medicines
Stock Code06160
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家商業階段的生物技術公司,專注於開發及商業化用於治療癌症的創新型分子靶向及腫瘤免疫治療藥物。我們內部開發的主要候選藥物處於臨床後期階段,並於中國銷售三種授權許可藥物。
Listing Date2018-08-08
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市昌平區中關村生命科學園科學園路30號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.beigene.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingYes (NASDAQ)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 108.00 / shares
Offer Price RangeTo be extracted
Lot Size100 shares
Entry ThresholdTo be extracted
Par ValueRMB 0.0001 / shares
Offer Period2018-07-30 to 2018-08-02
Global Offering Shares65,600,000 shares
HK Public Offer Shares (Initial)5,904,000 shares (9.0%)
Public Offer Lots (Initial)59,040lots (Pool A29,520lots,Pool B29,520lots)
International Placing Shares (Initial)59,696,000 shares (91.0%)
Offer Ratio~9.0%
Total Shares Post-IPO767,163,184 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share31.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 7,084,800,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 292.18B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 79,017,807,952
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status截至2017年12月31日止年度,BeiGene, Ltd.應佔虧損淨額約96.0百萬美元。
Period-End Cash Balance約239.6百萬美元(2017年12月31日現金及現金等價物)
Listing Expenses~HK$ 280,300,000
Listing Expenses / Funds Raised~3.96%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 USD
Income Statement
Item 201620172018-03
Revenue 1,070254,69432,544
Cost of sales 0-98,033-4,550
Other income and gains, net 44321,077814
Operating profit -117,060-82,150-110,809
Net finance costs 383-4,1081,552
Profit before tax -119,163-65,137-108,528
Income tax expense -54-30,730-3,412
Profit for the year -119,217-95,867-105,116
Profit attributable to owners -119,217-96,034-104,596
Balance Sheet
Item 201620172018-03
Cash and cash equivalents 87,514239,602490,634
Trade and bills receivables 029,42823,485
Inventories 010,9307,498
Total current assets 374,399929,8041,585,702
Total assets 405,8131,034,1981,708,927
Total current liabilities 35,058149,988141,896
Total liabilities 52,906352,258350,205
Total equity 352,907681,9401,358,722
Equity attributable to owners 352,907667,1431,344,381
Interest-bearing borrowings 17,284164,715173,681
Cash Flow Statement
Item 201620172018-03
Net cash from operating activities -89,51312,752-104,501
Net cash from investing activities -221,848-356,319-394,352
Net cash from financing activities 380,902490,356763,901
Net increase in cash 69,645152,088268,492
Purchase of PP&E -23,502-46,374-9,696
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 107.0
First Day OpenHK$ 108.0
First Day Change-0.93%
First Day Volume6857700.0
First Day Turnover727956000.0
Use of Proceeds
1、75%(或4,857.4百萬港元)用于zanubrutinib、tislelizumab及pamiparib: 2、15%或(或971.5百萬港元)將用于透過內部研究及外部授權及業務發展合作,為我們在癌癥及其他潛在治療領域的產品組合持續擴充提供資金; 3、10%或(或647.6百萬港元)用作營運資金、拓展內部能力及一般企業目的。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Overall Coordinators (4)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Credit Suisse (Hong Kong) Limited CE AAO017 中信里昂证券有限公司 CE AAB893
Joint Bookrunners (7)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Credit Suisse (Hong Kong) Limited CE AAO017 中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 Deutsche Bank AG, Hong Kong Branch CE AAK077 UBS Securities Hong Kong Limited CE BIN466
Joint Lead Managers (8)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Credit Suisse (Hong Kong) Limited CE AAO017 中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 Deutsche Bank AG, Hong Kong Branch CE AAK077 UBS Securities Hong Kong Limited CE BIN466 China Renaissance Securities (Hong Kong) Limited CE AZX839

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Ally Bridge LB Healthcare Master Fund Limited 196,225,200 HKD — 2.77% — 6 months 2019-02-08
2 Baker Brothers Life Sciences, L.P. 627,922,800 HKD — 8.86% — 6 months 2019-02-08
3 GIC Private Limited 784,900,800 HKD — 11.08% — 6 months 2019-02-08
4 Hillhouse Funds 585,792,000 HKD — 8.27% — 6 months 2019-02-08

Directors & Management

PositionChinese nameEnglish Name
Chairman歐雷強—
Company Secretary周慶齡—
No director data available.

Major Shareholders

Major Shareholders & HoldingsJulian C. Baker及Felix J. Baker各持有約21.07%;Baker Bros. Advisors (GP) LLC及Baker Bros. Advisors LP各持有約21.06%;Baker Brothers Life Sciences, L.P.持有18.93%;歐雷強持有10.84%;Hillhouse Capital Management Ltd.持有9.98%。
About this page

This page shows Beone Medicines (06160) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect